| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 126 | 136 | 102 | 105 | 118 | 119 | 81 | 100 | 114 | 131 | 150 | 173 | 164 | 176 | 123 | 61 | 65 | 160 | 151 | 151 | 136 | 167 | 163 | 248 | 166 | 198 | 176 | 250 | 197 |
| Expenses | 101 | 110 | 76 | 88 | 94 | 96 | 60 | 82 | 91 | 107 | 114 | 130 | 119 | 128 | 94 | 65 | 65 | 146 | 130 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 |
| EBITDA | 24 | 27 | 26 | 16 | 24 | 23 | 21 | 18 | 22 | 25 | 35 | 42 | 46 | 48 | 29 | -4 | 0 | 14 | 21 | 25 | 27 | 29 | 31 | 35 | 35 | 33 | 35 | 42 | 40 |
| Operating Profit % | 19 % | 19 % | 25 % | 15 % | 20 % | 19 % | 25 % | 15 % | 19 % | 18 % | 23 % | 24 % | 27 % | 27 % | 22 % | -7 % | -1 % | 9 % | 12 % | 16 % | 19 % | 17 % | 18 % | 14 % | 20 % | 16 % | 19 % | 16 % | 20 % |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 |
| Profit Before Tax | 16 | 19 | 19 | 8 | 15 | 14 | 13 | 9 | 14 | 16 | 27 | 34 | 33 | 35 | 16 | -16 | -13 | 1 | 7 | 11 | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 |
| Tax | 9 | 9 | 9 | -5 | 8 | 5 | 5 | 2 | 7 | 5 | 5 | 11 | 9 | 12 | 7 | -23 | 0 | 3 | 3 | 4 | 3 | 3 | 5 | 5 | 5 | 5 | 4 | 8 | 4 |
| Net Profit | 7 | 10 | 9 | 13 | 8 | 10 | 8 | 6 | 7 | 11 | 21 | 23 | 24 | 23 | 9 | 6 | -13 | -2 | 4 | 6 | 9 | 12 | 12 | 17 | 17 | 14 | 18 | 20 | 21 |
| EPS in ₹ | 0.85 | 1.19 | 1.11 | 1.57 | 0.92 | 1.17 | 0.90 | 0.76 | 0.83 | 1.30 | 2.53 | 2.73 | 2.78 | 2.72 | 1.07 | 0.73 | -1.51 | -0.24 | 0.44 | 0.73 | 1.10 | 1.39 | 1.36 | 2.04 | 1.95 | 1.67 | 2.15 | 2.40 | 2.31 |
SMS Pharmaceuticals
SMS Pharmaceuticals
251.68
-18.95
(-7.00%)
Market Cap
2,231.20 Cr
EPS
8.16
PE Ratio
30.62
Dividend Yield
0.16 %
Industry
Healthcare52 Week High
390.85
52 Week Low
176.05
PB Ratio
3.50
Debt to Equity
0.50
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
SMS Pharmaceuticals Promoters Convert 5 Crore Warrants Into Equity SharesSep 13, 2025
SMS Pharmaceuticals Limited disclosed that promoters Trilok Potluri and Vamsi Krishna Potluri converted 50 lakh warrants into equity shares through preferential allotment on September 10, 2025. Each promoter converted 25 lakh warrants into an equal number of equity shares. Following this conversion, the promoter group's total shareholding increased from 41.35% to 46.99% of the company's voting capital. The company's total equity share capital expanded from 8.87 crore shares to 9.37 crore shares, each with a face value of Re 1. The conversion was completed after receipt of the remaining balance amount for the warrants.
SMS Pharma has received an Establishment Inspection Report (EIR) from the US FDA with 'No Action Indicated' status for its Central Laboratory Analytical Services facility in Hyderabad. This classification indicates that the FDA found no significant regulatory issues during its inspection of the laboratory facility.
SMS Pharma received a USFDA Establishment Inspection Report (EIR) with "No Action Indicated" status for its Central Laboratory Analytical Services facility in Hyderabad. This classification indicates that the FDA found no significant regulatory violations during their inspection of the laboratory facility.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
35.43 %
Net Income Growth
1,161.54 %
Cash Flow Change
63.03 %
ROE
991.67 %
ROCE
192.43 %
EBITDA Margin (Avg.)
50.49 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Fixed Assets | 370 | 291 | 279 | 281 | 281 | 457 | 438 | 412 | 437 | 568 |
| Current Assets | 248 | 157 | 169 | 208 | 219 | 309 | 377 | 411 | 534 | 555 |
| Capital Work in Progress | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 |
| Investments | 0 | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 285 |
| Other Assets | 272 | 166 | 187 | 232 | 260 | 321 | 389 | 424 | 556 | 0 |
| Total Liabilities | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Current Liabilities | 200 | 147 | 122 | 143 | 145 | 195 | 197 | 255 | 332 | 324 |
| Non Current Liabilities | 162 | 91 | 97 | 94 | 115 | 206 | 193 | 164 | 166 | 189 |
| Total Equity | 294 | 255 | 285 | 322 | 348 | 411 | 470 | 461 | 536 | 640 |
| Reserve & Surplus | 285 | 246 | 276 | 314 | 340 | 402 | 462 | 452 | 499 | 631 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Cash Flow
| Cash Flow | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -9 | 1 | 0 | 2 | -5 | 31 | 6 | -39 | 29 |
| Investing Activities | -97 | -39 | -17 | -35 | -43 | -152 | -27 | -30 | -52 |
| Operating Activities | 61 | 74 | 32 | 50 | 40 | 90 | 45 | 23 | 50 |
| Financing Activities | 27 | -33 | -15 | -13 | -2 | 92 | -12 | -32 | 31 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 64.17 % | 64.17 % | 64.17 % | 64.29 % | 64.32 % | 64.32 % | 64.32 % | 64.67 % | 64.67 % | 64.67 % | 64.67 % | 66.26 % | 66.26 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.60 % | 0.59 % | 0.17 % | 0.17 % | 0.52 % | 0.31 % | 0.08 % | 0.03 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.98 % | 2.13 % | 2.55 % | 2.55 % | 2.43 % | 3.03 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 26.92 % | 26.87 % | 26.23 % | 26.72 % | 26.38 % | 29.65 % | 28.84 % | 28.82 % | 29.00 % | 29.04 % | 29.08 % | 29.22 % | 27.93 % | 27.81 % | 27.04 % | 27.38 % | 26.35 % | 25.89 % |
| Others | 5.79 % | 5.84 % | 6.47 % | 5.99 % | 6.33 % | 6.18 % | 6.98 % | 7.00 % | 6.70 % | 6.64 % | 6.01 % | 5.88 % | 5.25 % | 5.22 % | 5.23 % | 5.09 % | 4.87 % | 4.78 % |
| No of Share Holders | 19,878 | 25,601 | 24,608 | 24,959 | 27,516 | 26,638 | 26,491 | 26,526 | 25,537 | 24,653 | 25,246 | 25,341 | 30,140 | 31,780 | 33,136 | 34,973 | 35,332 | 33,652 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.2 | 0.25 | 0.25 | 0.25 | 0.3 | 0.3 | 0.3 | 0.4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.27 | 0.4 | 0.93 | 0.2 | 0.32 | 0.53 | 0.17 | 0.19 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Sept 2025 |  Annual General Meeting | NA | 29 Sept 2025 | 223.95 | 251.68 |
| 24 Sept 2021 |  Dividend | ₹ 0.30 /share | 22 Sept 2021 | 167.60 | 157.70 |
| 23 Sept 2022 | Dividend | ₹ 0.30 /share | 22 Sept 2022 | 84.35 | 89.80 |
| 22 Sept 2023 | Dividend | ₹ 0.30 /share | 22 Sept 2023 | 84.40 | 121.50 |
| 06 Mar 2024 |  Extraordinary General Meeting | NA | 06 Mar 2024 | 146.45 | 181.90 |
| 23 Sept 2024 | Dividend | ₹ 0.40 /share | 23 Sept 2024 | 209.90 | 368.65 |
| 30 Sept 2024 | Annual General Meeting | NA | 30 Sept 2024 | 312.55 | 351.20 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 294.60 | 305.90 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 205.15 | 200.02 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 262.50 | 270.37 |
| 09 Aug 2025 | Quarterly Result Announcement | NA | 09 Aug 2025 | 228.91 | 223.95 |
| 22 Sept 2025 | Dividend | ₹ 0.40 /share | 22 Sept 2025 | 270.37 | 292.50 |
Announcements
Closure of Trading Window
9 hours ago
9 hours agoDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 13, 2025
Sep 13, 2025Clarification On Volume/Price MovementSep 12, 2025
Sep 12, 2025Clarification sought from SMS Pharmaceuticals LtdSep 12, 2025
Sep 12, 2025Conversion Of 5000000 Warrants Into Equity SharesSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Conversion of SecuritiesSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Sep 08, 2025Dispatch Of Letter With Web-Link To Annual ReportSep 06, 2025
Sep 06, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 06, 2025
Sep 06, 2025Reg. 34 (1) Annual Report.Sep 06, 2025
Sep 06, 2025Notice Of 37Th Annual General Meeting And Annual Report For The FY 2024-25Sep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 22, 2025
Aug 22, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 11, 2025
Aug 11, 2025Investor Presentation On Financial ResultsAug 10, 2025
Aug 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 10, 2025
Aug 10, 2025Results For The Quarter Ended June 30 2025Aug 09, 2025
Aug 09, 2025Record Date For The Purpose Of Determining The Members Eligible To Receive Dividend For The Financial Year 2024-25Aug 09, 2025
Aug 09, 2025Statement Of Deviation Or Variation For The Quarter Ended June 30 2025Aug 09, 2025
Aug 09, 2025Board Meeting Outcome for Outcome Of Board Meeting And Financial ResultsAug 09, 2025
Aug 09, 2025Board Meeting Intimation for Unaudited (Standalone And Consolidated) Financial Results For The First Quarter Ended On 30Th June 2025Aug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 - Reminder Letter For Transfer Of Shares To Investor Education And Protection Fund (IEPF)Jul 08, 2025
Jul 08, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 01, 2025
Jul 01, 2025Board Meeting Outcome for Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Technical Indicators
RSI(14)
Neutral 43.42
ATR(14)
Volatile 13.84
STOCH(9,6)
Neutral 30.93
STOCH RSI(14)
Oversold 8.57
MACD(12,26)
Bearish -2.67
ADX(14)
Strong Trend 49.25
UO(9)
Bearish 30.32
ROC(12)
Downtrend And Accelerating -6.10
WillR(14)
Oversold -88.71
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.05% | -2 | 0.00% | 0.00% | |
 Quant Healthcare Fund Direct - Growth | 5.14% | 0 | 0.37% | 0.23% | |
| Quant Small Cap Fund Direct Plan-Growth | 0.15% | 0 | 0.01% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
